{
    "clinical_study": {
        "@rank": "157979", 
        "arm_group": [
            {
                "arm_group_label": "Hypoglycaemia / euglycaemia clamp", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Euglycaemia clamp / hypoglycaemia", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to compare cognitive function and\n      associated brain activation patterns during an acute hypoglycaemic episode and during\n      euglycaemia (normal blood glucose concentration). Additionally, the purpose is to assess\n      cognitive function in the recovery phase after hypoglycaemia or euglycaemia, respectively,\n      in subjects with type 1 diabetes."
        }, 
        "brief_title": "A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Right-handed subjects\n\n          -  Type 1 diabetes mellitus for at least 12 months\n\n          -  Treated with multiple daily insulin injections or continuous subcutaneous insulin\n             infusion (CSII) for at least 12 months\n\n          -  Body mass index 18.0-28.0 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Current tobacco user (any smoking or use of nicotinic products within 3 months prior\n             to screening)\n\n          -  Visual impairment or auditory impairment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789593", 
            "org_study_id": "NN1250-4001", 
            "secondary_id": "U1111-1131-8749"
        }, 
        "intervention": {
            "arm_group_label": [
                "Hypoglycaemia / euglycaemia clamp", 
                "Euglycaemia clamp / hypoglycaemia"
            ], 
            "description": "Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid\u00ae)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test", 
            "intervention_name": "glucose clamp", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 4, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "\u00c5rhus C", 
                    "country": "Denmark", 
                    "zip": "8000"
                }
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Louise Maymann Nitze", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Digit Symbol Substitution Test (DSST) score", 
            "safety_issue": "No", 
            "time_frame": "Average score during hypoglycaemia and/or euglycaemia measured 70-93 minutes after induction of hypoglycaemia and/or euglycaemia"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789593"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Regional cerebral blood flow (rCBF) score", 
                "safety_issue": "No", 
                "time_frame": "Average score during hypoglycaemia and/or euglycaemia measured 70-93 minutes after induction of hypoglycaemia and/or euglycaemia"
            }, 
            {
                "measure": "Paced Auditory Serial Addition Task (PASAT) score", 
                "safety_issue": "No", 
                "time_frame": "During recovery from hypoglycaemia and/or euglycaemia measured 75-90 min after euglycaemia has been restored"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}